Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $12 to $8.